{"nctId":"NCT00343460","briefTitle":"APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","startDateStruct":{"date":"2006-06"},"conditions":["Nausea and Vomiting","Unspecified Adult Solid Tumor, Protocol Specific"],"count":1428,"armGroups":[{"label":"Arm I","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: dexamethasone","Drug: Palonosetron Hydrochloride","Other: placebo"]},{"label":"Arm II","type":"EXPERIMENTAL","interventionNames":["Drug: APF530","Drug: dexamethasone","Other: placebo"]},{"label":"Arm III","type":"EXPERIMENTAL","interventionNames":["Drug: APF530","Drug: dexamethasone","Other: placebo"]}],"interventions":[{"name":"APF530","otherNames":[]},{"name":"dexamethasone","otherNames":[]},{"name":"Palonosetron Hydrochloride","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed malignant disease\n\n  * No head and neck cancer or upper gastrointestinal cancer\n* Scheduled to receive a single day of moderately or highly emetogenic chemotherapy regimen (for ≤ 4 courses)\n\n  * Chemotherapy administration ≤ 4 hours\n  * Duration of each course ≤ 28 days\n  * Causing nausea and vomiting in 30-100% of patients if untreated according to Hesketh algorithm\n* Must be able to receive standardized doses of dexamethasone for the prevention of emesis during study treatment\n* No greater than mild nausea or any vomiting within 24 hours before beginning study treatment\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No known allergy or hypersensitivity to other selective 5-HT3 receptor antagonists or local anesthetics\n* QTc interval ≤ 500 ms\n* No cardiac abnormality predisposing the patient to arrhythmia\n* No psychological problem that, in the opinion of the investigator, is severe enough to preclude study participation\n* No recent history (i.e., ≤ 1 year) of alcohol or drug abuse\n* No concurrent condition that, in the opinion of the investigator, could affect assessment of study medication or interfere with the nausea/vomiting response (e.g., severe renal or hepatic impairment)\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No radiotherapy 7 days prior to, during, and 5 days after completion of study treatment\n* More than 7 days since prior chemotherapy\n* More than 7 days since prior and no concurrent prohibited medications (e.g., CYP3A4 inhibitors or other antiemetic medications)\n* More than 7 days since prior antinausea medications\n* More than 30 days since prior treatment on an investigational trial\n* No other concurrent corticosteroids or dexamethasone at a different dose than study treatment\n* No concurrent use of APF530, palonosetron hydrochloride, or aprepitant as rescue medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1","description":"Complete Response is defined as no emetic episodes and no use of rescue medications","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"163","spread":null},{"groupId":"OG002","value":"156","spread":null},{"groupId":"OG003","value":"178","spread":null},{"groupId":"OG004","value":"195","spread":null},{"groupId":"OG005","value":"192","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1","description":"Complete Response is defined as no emetic episodes and no use of rescue medications","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"125","spread":null},{"groupId":"OG002","value":"120","spread":null},{"groupId":"OG003","value":"148","spread":null},{"groupId":"OG004","value":"164","spread":null},{"groupId":"OG005","value":"158","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1","description":"Complete control is defined as complete response with no more than mild nausea.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"152","spread":null},{"groupId":"OG002","value":"147","spread":null},{"groupId":"OG003","value":"170","spread":null},{"groupId":"OG004","value":"183","spread":null},{"groupId":"OG005","value":"184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"107","spread":null},{"groupId":"OG003","value":"138","spread":null},{"groupId":"OG004","value":"150","spread":null},{"groupId":"OG005","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"127","spread":null},{"groupId":"OG004","value":"138","spread":null},{"groupId":"OG005","value":"136","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1","description":"TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1.\n\nTR during delayed-onset phase is defined as Complete Response with no nausea during \\>24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"113","spread":null},{"groupId":"OG003","value":"141","spread":null},{"groupId":"OG004","value":"146","spread":null},{"groupId":"OG005","value":"158","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"73","spread":null},{"groupId":"OG003","value":"115","spread":null},{"groupId":"OG004","value":"113","spread":null},{"groupId":"OG005","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"65","spread":null},{"groupId":"OG003","value":"103","spread":null},{"groupId":"OG004","value":"101","spread":null},{"groupId":"OG005","value":"117","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Emetic Episodes","description":"Number of Emetic Episodes - days 1-5","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"8.03"},{"groupId":"OG001","value":"3.1","spread":"9.35"},{"groupId":"OG002","value":"2.1","spread":"5.12"},{"groupId":"OG003","value":"2.3","spread":"6.69"},{"groupId":"OG004","value":"2.4","spread":"7.87"},{"groupId":"OG005","value":"2.5","spread":"7.15"}]}]}]},{"type":"SECONDARY","title":"Time to First Treatment Failure","description":"Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.738","spread":null},{"groupId":"OG001","value":"0.763","spread":null},{"groupId":"OG002","value":"0.755","spread":null},{"groupId":"OG003","value":"0.781","spread":null},{"groupId":"OG004","value":"0.811","spread":null},{"groupId":"OG005","value":"0.803","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.636","spread":null},{"groupId":"OG001","value":"0.659","spread":null},{"groupId":"OG002","value":"0.635","spread":null},{"groupId":"OG003","value":"0.706","spread":null},{"groupId":"OG004","value":"0.723","spread":null},{"groupId":"OG005","value":"0.714","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.533","spread":null},{"groupId":"OG001","value":"0.564","spread":null},{"groupId":"OG002","value":"0.567","spread":null},{"groupId":"OG003","value":"0.649","spread":null},{"groupId":"OG004","value":"0.685","spread":null},{"groupId":"OG005","value":"0.672","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.485","spread":null},{"groupId":"OG001","value":"0.550","spread":null},{"groupId":"OG002","value":"0.534","spread":null},{"groupId":"OG003","value":"0.618","spread":null},{"groupId":"OG004","value":"0.668","spread":null},{"groupId":"OG005","value":"0.634","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.485","spread":null},{"groupId":"OG001","value":"0.540","spread":null},{"groupId":"OG002","value":"0.529","spread":null},{"groupId":"OG003","value":"0.600","spread":null},{"groupId":"OG004","value":"0.647","spread":null},{"groupId":"OG005","value":"0.620","spread":null}]}]}]},{"type":"SECONDARY","title":"First and Overall Use of Rescue Medication","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"35","spread":null},{"groupId":"OG004","value":"23","spread":null},{"groupId":"OG005","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"63","spread":null},{"groupId":"OG003","value":"60","spread":null},{"groupId":"OG004","value":"42","spread":null},{"groupId":"OG005","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"71","spread":null},{"groupId":"OG004","value":"45","spread":null},{"groupId":"OG005","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)","description":"Maximum severity of nausea, days 1-5","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"105","spread":null},{"groupId":"OG004","value":"102","spread":null},{"groupId":"OG005","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"68","spread":null},{"groupId":"OG003","value":"53","spread":null},{"groupId":"OG004","value":"68","spread":null},{"groupId":"OG005","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"48","spread":null},{"groupId":"OG004","value":"37","spread":null},{"groupId":"OG005","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"28","spread":null},{"groupId":"OG005","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses","description":"Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles\n\nComplete Response is defined as no emetic episodes and no use of rescue medications","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life and the Impact of Nausea and Vomiting on Day 5","description":"Functional Living Index","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"127","spread":null},{"groupId":"OG002","value":"120","spread":null},{"groupId":"OG003","value":"142","spread":null},{"groupId":"OG004","value":"142","spread":null},{"groupId":"OG005","value":"159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"162","spread":null},{"groupId":"OG002","value":"160","spread":null},{"groupId":"OG003","value":"173","spread":null},{"groupId":"OG004","value":"182","spread":null},{"groupId":"OG005","value":"191","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1","description":"Subject who were very satisfied on Day 1","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"128","spread":null},{"groupId":"OG004","value":"128","spread":null},{"groupId":"OG005","value":"135","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":464},"commonTop":["Injection site bruising","Constipation","Fatigue","Anaemia","Nausea"]}}}